文献速递冠心病外科

术中替格瑞洛清除装置减少围术期出血的随机假对照试验

Randomized, sham-controlled trial of intraoperative ticagrelor removal to reduce perioperative bleeding.
PubMed 文献 · J Thorac Cardiovasc Surg · 2026-01-23

针对替格瑞洛停药2天内接受心脏手术的高出血风险患者,随机分配至术中DrugSorb-ATR或假对照组。主要安全终点达标,但总体和CABG人群主要疗效终点未达;预设CABG人群补充疗效终点显示严重出血事件显著减少。

要点

  • 替格瑞洛停药2天内手术者术中应用DrugSorb-ATR安全。
  • 总体人群主要疗效复合终点未显著改善。
  • 预设CABG人群补充终点显示严重出血减少。

核心结论

  • 术中DrugSorb-ATR在替格瑞洛停药2天内手术患者中安全,总体主要疗效终点未达,但预设CABG人群严重出血事件显著减少。

研究设计与样本

  • 随机、假对照试验,140例随机,132例接受手术并置入研究装置,92%为孤立CABG,平均年龄65±5岁,女性15%。

主要发现

  • 主要安全终点达标,两组不良事件相似。
  • 总体人群主要疗效终点未达(WR 1.07,95%CI 0.72-1.58,P=.748)。
  • CABG人群主要疗效终点未达(WR 1.33,95%CI 0.86-2.04,P=.202)。
  • CABG人群补充疗效终点达标(WR 1.59,95%CI 1.02-2.46,P=.041),大号胸管引流出血事件(P=.016)和重大出血(P=.041)显著减少。
  • 预防一次重大出血需治疗人数为6。

关键数值与推荐

  • 主要疗效终点采用UDPB出血事件和24小时胸管引流的复合终点,层次胜率法分析。
  • 补充疗效终点在CABG人群达到显著(WR 1.59,95%CI 1.02-2.46,P=.041)。
  • 重大出血定义为严重出血事件或24小时胸管引流≥1 L的复合终点(P=.041)。

临床怎么用

  • 对于替格瑞洛停药2天内需行CABG的高出血风险患者,可考虑术中应用DrugSorb-ATR以减少严重出血。

局限性

  • 总体和CABG人群主要疗效终点未达显著。
  • 样本量较小(140例随机),92%为孤立CABG,结果外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients on ticagrelor who are undergoing cardiac surgery before completing guideline-recommended washout are at high risk for severe bleeding. This study evaluated whether a novel drug removal device reduces bleeding in patients operated within 2 days from ticagrelor discontinuation. METHODS: Eligible patients were randomized 1:1 to intraoperative DrugSorb-ATR or sham control. Primary safety end point was adverse events at 30 days. Efficacy was assessed by composite end points comprising bleeding events using Universal Definition of Perioperative Bleeding (UDPB) and 24-hour chest tube drainage (CTD) in the overall and isolated coronary artery bypass grafting (CABG) populations with a hierarchical win ratio (WR) method. RESULTS: In total, 140 patients were randomized; 132 had surgery and received a study device; and 92% were isolated CABG. Mean age was 65 ± 5 years, and 15% were female. The primary safety end point was met, with similar adverse events reported between groups. The primary efficacy end point was not met in the overall or CABG populations (Win ratio [WR], 1.07; 95% CI, 0.72-1.58; P = .748 and WR, 1.33; 95% CI, 0.86-2.04; P = .202 respectively). The supplementary efficacy end point was met in the CABG population (WR, 1.59; 95% CI, 1.02-2.46, P = .041) with significant reductions also shown in large CTD bleeding events (P = .016) and major bleeding, a composite of severe bleeding events or 24-hour CTD ≥1 L (P = .041). The number needed to treat to prevent a major bleed was 6. CONCLUSIONS: Intraoperative use of DrugSorb-ATR is safe in patients operated within 2 days of ticagrelor discontinuation. Although the primary end point was not met in the overall population, there were significant reductions in severe bleeding events in the prespecified CABG population.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Mack MJ, Whitlock R, Chu MWA, et al. Randomized, sham-controlled trial of intraoperative ticagrelor removal to reduce perioperative bleeding. J Thorac Cardiovasc Surg. 2026. PMID: 41581856. doi:10.1016/j.jtcvs.2026.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。